echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Japan's machete cut prices and doubled the speed of price reduction of old medicine

    Japan's machete cut prices and doubled the speed of price reduction of old medicine

    • Last Update: 2017-11-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: ihealth 2017-11-27 the new drug price policy announced by housheng province to the Chinese Medicine Association on Wednesday is a headache for drug companies with many mature products The new deal clearly states that from 2021, three years later, Japan will reduce the drug price once every two years, and speed up to reduce the price every year Especially those old drugs, that is, mature products, will face more severe bargaining According to the current policy, if a new drug has been on the market for less than 15 years and no generic drugs have been on the market, these so-called new drugs can be protected from the suffering of such bargaining every year The new policy will make these pharmaceutical companies enjoying "special care" face more stringent scrutiny After the implementation of the new policy, only those pharmaceutical companies that have been delayed in approval in the Japanese market can be protected from price cuts In addition, the most popular new drugs, which sell more than 35 billion yen (about 312 million US dollars) in the Japanese market, may face four price cuts a year Moreover, the price of medicine will incline to the real innovative medicine According to Japan's Pharmaceutical Manufacturers Association (JPMA), new drugs that "can really improve the quality of medical care" can avoid annual price cuts The Ministry also said it would reassess which drugs are "truly innovative" and which new drugs can get discounts without price cuts For example: are generic drugs innovative? Should it be "Japan new" or "global new"? How to encourage pharmaceutical companies to carry out clinical trials in China and develop more domestic original new drugs At present, there are too many new drug titles Of all the drugs, one third are entitled "new drug" However, the industry is quite critical of the new drug price policy They believe that this policy may crack down on innovation enthusiasm and pour cold water on enterprises developing innovative therapies in Japan Reference article: https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.